Back to Results
First PageMeta Content
Pharmaceutical industry / Hospira / Antiemetics / Generic drug / Food and Drug Administration / United States patent law / Abbreviated New Drug Application / Patent infringement / 5-HT3 antagonist / Pharmaceutical sciences / Pharmacology / Clinical research


Case 3:15-cv[removed]MLC-DEA Document 1 Filed[removed]Page 1 of 64 PageID: 1 Charles M. Lizza William C. Baton SAUL EWING LLP One Riverfront Plaza, Suite 1520
Add to Reading List

Document Date: 2015-03-30 01:51:57


Open Document

File Size: 124,73 KB

Share Result on Facebook

City

South San Francisco / Lugano-Pazzallo / Lake Forest / Newark / New York / /

Company

Plaintiffs Helsinn Healthcare S.A. / NEW JERSEY HELSINN HEALTHCARE S.A. / Plaintiff Helsinn Healthcare S.A. / Lizza William C. Baton SAUL EWING LLP / E. Waddell LOEB & LOEB LLP / Defendant Hospira Inc. / HOSPIRA INC. / Helsinn / PAUL HASTINGS LLP / Roche Palo Alto LLC / Plaintiff Roche Palo Alto LLC / /

Country

Switzerland / United States / /

Event

FDA Phase / /

Facility

Baton SAUL EWING LLP One Riverfront Plaza / /

IndustryTerm

brand palonosetron hydrochloride intravenous solutions / generic pharmaceutical drugs / mL palonosetron hydrochloride intravenous solutions / generic drug products / /

MedicalCondition

injury / /

Organization

UN Court / United States Food and Drug Administration / /

Person

Eric W. Dittmann David / David M. Conca Gary Ji Angela / Angela C. Ni / Bruce M. Wexler Eric / Malley / Jr. / /

Position

Counsel / /

Product

Aloxi / Federal Food / Approved Drug / Aloxi® / /

ProvinceOrState

New Jersey / Illinois / Delaware / New York / California / New / /

SocialTag